EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis-Reference-Cited by-同舟云学术

EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

Published:2012-09 Issue:3 Volume:22 Page:304-317
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Ardito Christine M.,Grüner Barbara M.,Takeuchi Kenneth K.,Lubeseder-Martellato Clara,Teichmann Nicole,Mazur Pawel K.,DelGiorno Kathleen E.,Carpenter Eileen S.,Halbrook Christopher J.,Hall Jason C.,Pal Debjani,Briel Thomas,Herner Alexander,Trajkovic-Arsic Marija,Sipos Bence,Liou Geou-Yarh,Storz Peter,Murray Nicole R.,Threadgill David W.,Sibilia Maria,Washington M. Kay,Wilson Carole L.,Schmid Roland M.,Raines Elaine W.,Crawford Howard C.,Siveke Jens T.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference52 articles.

1. Role of epidermal growth factor receptor signaling in RAS-driven melanoma;Bardeesy;Mol. Cell. Biol.,2005

2. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse;Bardeesy;Proc. Natl. Acad. Sci. USA,2006

3. Role of Shc in the activation of Ras in response to epidermal growth factor and nerve growth factor;Basu;Oncogene,1994

4. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras;Carrière;Biochem. Biophys. Res. Commun.,2009

5. Measuring Ras-family GTP levels in vivo—running hot and cold;Castro;Methods,2005

Cited by 438 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. YAP‐LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine;Molecular Carcinogenesis;2024-07-17

2. Down-Regulation of AKT Proteins Slows the Growth of Mutant-KRAS Pancreatic Tumors;Cells;2024-06-19

3. Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma;International Journal of Molecular Sciences;2024-06-16

4. Down-regulation of AKT proteins slows the growth of mutant-KRAS pancreatic tumors;2024-05-05

5. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial;European Journal of Cancer;2024-04